Rosen Law Firm Encourages Nektar Therapeutics Investors to Secure Counsel Before Deadline

Investors who purchased Nektar securities between February 26, 2025 and December 15, 2025 may be eligible for compensation.

Mar. 17, 2026 at 12:05am

Got story updates? Submit your updates here. ›

Rosen Law Firm, a global investor rights law firm, has announced a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025. The lawsuit alleges that Nektar made false and/or misleading statements about the REZOLVE-AA trial, including issues with enrollment and protocol standards that could negatively impact the trial's results. Investors who purchased Nektar securities during this period may be entitled to compensation.

Why it matters

This case highlights the importance of transparency and accurate disclosures from publicly traded companies. Investors rely on this information to make informed decisions, and any misleading statements can lead to significant losses. The class action lawsuit aims to hold Nektar accountable and provide compensation to affected investors.

The details

According to the lawsuit, Nektar allegedly made false and/or misleading statements about the REZOLVE-AA trial, including that enrollment had not followed applicable instructions and protocol standards, and that this was likely to have a significant negative impact on the trial's results. The lawsuit claims that as a result, Nektar's public statements were materially false and misleading at all relevant times.

  • The class period is from February 26, 2025 to December 15, 2025, both dates inclusive.
  • Investors must move the Court no later than May 5, 2026 to serve as lead plaintiff.

The players

Rosen Law Firm

A global investor rights law firm that has announced the class action lawsuit on behalf of Nektar Therapeutics investors.

Nektar Therapeutics

A biopharmaceutical company that is the subject of the class action lawsuit related to alleged false and/or misleading statements about the REZOLVE-AA trial.

Got photos? Submit your photos here. ›

What they’re saying

“We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel.”

— Phillip Kim, Esq., Attorney

What’s next

Investors who purchased Nektar securities during the class period must move the Court no later than May 5, 2026 to serve as lead plaintiff.

The takeaway

This case highlights the importance of transparency and accurate disclosures from publicly traded companies, as investors rely on this information to make informed decisions. The class action lawsuit aims to hold Nektar accountable and provide compensation to affected investors.